Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Total Liabilities 2010-2024 | IRWD

Ironwood Pharmaceuticals total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
  
Ironwood Pharmaceuticals Annual Total Liabilities
(Millions of US $)
2023 $817
2022 $448
2021 $521
2020 $497
2019 $496
2018 $528
2017 $596
2016 $643
2015 $524
2014 $241
2013 $241
2012 $86
2011 $99
2010 $142
2009 $461
Ironwood Pharmaceuticals Quarterly Total Liabilities
(Millions of US $)
2024-09-30 $701
2024-06-30 $717
2024-03-31 $769
2023-12-31 $817
2023-09-30 $850
2023-06-30 $950
2023-03-31 $448
2022-12-31 $448
2022-09-30 $449
2022-06-30 $443
2022-03-31 $566
2021-12-31 $521
2021-09-30 $499
2021-06-30 $495
2021-03-31 $489
2020-12-31 $497
2020-09-30 $486
2020-06-30 $480
2020-03-31 $476
2019-12-31 $496
2019-09-30 $487
2019-06-30 $535
2019-03-31 $601
2018-12-31 $528
2018-09-30 $614
2018-06-30 $662
2018-03-31 $589
2017-12-31 $596
2017-09-30 $643
2017-06-30 $700
2017-03-31 $672
2016-12-31 $643
2016-09-30 $673
2016-06-30 $619
2016-03-31 $512
2015-12-31 $524
2015-09-30 $513
2015-06-30 $514
2015-03-31 $237
2014-12-31 $241
2014-09-30 $238
2014-06-30 $229
2014-03-31 $230
2013-12-31 $241
2013-09-30 $242
2013-06-30 $245
2013-03-31 $267
2012-12-31 $86
2012-09-30 $64
2012-06-30 $80
2012-03-31 $85
2011-12-31 $99
2011-09-30 $107
2011-06-30 $120
2011-03-31 $127
2010-12-31 $142
2010-09-30 $136
2010-06-30 $149
2010-03-31 $149
2009-12-31 $461
2009-09-30 $425
2009-06-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.621B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $73.775B 28.39
Chugai Pharmaceutical (CHGCY) Japan $70.198B 27.35
Takeda Pharmaceutical (TAK) Japan $41.396B 8.62
Merck (MKKGY) Germany $18.461B 16.53
Sandoz Group AG (SDZNY) Switzerland $18.159B 0.00
Astellas Pharma (ALPMY) Japan $17.463B 16.08
United Therapeutics (UTHR) United States $16.079B 15.82
Neurocrine Biosciences (NBIX) United States $13.664B 36.18
Summit Therapeutics (SMMT) United States $13.569B 0.00
Shionogi (SGIOY) Japan $11.688B 11.71
Madrigal Pharmaceuticals (MDGL) United States $6.399B 0.00
Orion OYJ (ORINY) Finland $6.196B 17.42
Ionis Pharmaceuticals (IONS) United States $5.620B 0.00
Corcept Therapeutics (CORT) United States $5.359B 40.60
Crinetics Pharmaceuticals (CRNX) United States $4.891B 0.00
PTC Therapeutics (PTCT) United States $3.490B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.560B 11.60
Dyne Therapeutics (DYN) United States $2.473B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.401B 14.35
NewAmsterdam Pharma (NAMS) Netherlands $2.352B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $2.314B 0.00
Soleno Therapeutics (SLNO) United States $1.949B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.746B 0.00
Xencor (XNCR) United States $1.680B 0.00
Indivior (INDV) United States $1.591B 6.48
Evotec AG (EVO) Germany $1.559B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.531B 0.00
Guardian Pharmacy Services (GRDN) United States $1.382B 0.00
Ocular Therapeutix (OCUL) United States $1.328B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.294B 0.00
Harrow (HROW) United States $1.226B 0.00
Enliven Therapeutics (ELVN) United States $1.117B 0.00
Ardelyx (ARDX) United States $1.111B 0.00
ARS Pharmaceuticals (SPRY) United States $1.100B 0.00
Collegium Pharmaceutical (COLL) United States $0.982B 5.36
Avadel Pharmaceuticals (AVDL) Ireland $0.974B 0.00
Bioventus (BVS) United States $0.854B 26.97
Oruka Therapeutics (ORKA) United States $0.727B 0.00
Cronos Group (CRON) Canada $0.715B 0.00
Relay Therapeutics (RLAY) United States $0.713B 0.00
USANA Health Sciences (USNA) United States $0.662B 12.27
Elite Pharmaceuticals (ELTP) United States $0.609B 0.00
Altimmune (ALT) United States $0.582B 0.00
Savara (SVRA) United States $0.554B 0.00
Tourmaline Bio (TRML) United States $0.522B 0.00
Xeris Biopharma Holdings (XERS) United States $0.508B 0.00
OmniAb (OABI) United States $0.494B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.478B 0.00
Zevra Therapeutics (ZVRA) United States $0.456B 0.00
Verve Therapeutics (VERV) United States $0.437B 0.00
Siga Technologies (SIGA) United States $0.431B 5.03
Esperion Therapeutics (ESPR) United States $0.429B 0.00
ProKidney (PROK) United States $0.426B 0.00
Organogenesis (ORGO) United States $0.412B 0.00
Korro Bio (KRRO) United States $0.404B 0.00
KalVista Pharmaceuticals (KALV) United States $0.400B 0.00
Akebia Therapeutics (AKBA) United States $0.391B 0.00
Aquestive Therapeutics (AQST) United States $0.332B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.303B 122.93
Avita Medical (RCEL) United States $0.301B 0.00
Aldeyra Therapeutics (ALDX) United States $0.289B 0.00
Nature's Sunshine Products (NATR) United States $0.280B 16.63
Amylyx Pharmaceuticals (AMLX) United States $0.271B 0.00
4D Molecular Therapeutics (FDMT) United States $0.267B 0.00
Larimar Therapeutics (LRMR) United States $0.254B 0.00
Heron Therapeutics (HRTX) United States $0.233B 0.00
Innate Pharma SA (IPHYF) France $0.233B 0.00
Profound Medical (PROF) Canada $0.219B 0.00
Inhibikase Therapeutics (IKT) United States $0.212B 0.00
Acrivon Therapeutics (ACRV) United States $0.208B 0.00
Lexeo Therapeutics (LXEO) United States $0.200B 0.00
Aclaris Therapeutics (ACRS) United States $0.198B 0.00
Silence Therapeutics (SLN) United Kingdom $0.190B 0.00
Lyell Immunopharma (LYEL) United States $0.187B 0.00
MediWound (MDWD) Israel $0.186B 0.00
Nektar Therapeutics (NKTR) United States $0.174B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.162B 0.00
Nanobiotix S.A (NBTX) France $0.155B 0.00
CytoDyn (CYDY) United States $0.150B 0.00
Metagenomi (MGX) United States $0.144B 0.00
VAXART, INC (VXRT) United States $0.137B 0.00
Telomir Pharmaceuticals (TELO) United States $0.134B 0.00
Achieve Life Sciences (ACHV) Canada $0.131B 0.00
Galectin Therapeutics (GALT) United States $0.126B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.124B 0.00
Cassava Sciences (SAVA) United States $0.110B 0.00
Cardiol Therapeutics (CRDL) Canada $0.107B 0.00
Protara Therapeutics (TARA) United States $0.107B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.107B 0.00
Champions Oncology (CSBR) United States $0.104B 0.00
Regulus Therapeutics (RGLS) United States $0.102B 0.00
Inotiv (NOTV) United States $0.100B 0.00
Journey Medical (DERM) United States $0.097B 0.00
ElectroCore (ECOR) United States $0.095B 0.00
Avalo Therapeutics (AVTX) United States $0.094B 0.00
Pyxis Oncology (PYXS) United States $0.092B 0.00
Century Therapeutics (IPSC) United States $0.089B 0.00
Fractyl Health (GUTS) United States $0.088B 0.00
Karyopharm Therapeutics (KPTI) United States $0.082B 0.00
Context Therapeutics (CNTX) United States $0.082B 0.00
Assertio Holdings (ASRT) United States $0.080B 21.08
Arch Biopartners (ACHFF) Canada $0.078B 0.00
PMV Pharmaceuticals (PMVP) United States $0.078B 0.00
Unicycive Therapeutics (UNCY) United States $0.074B 0.00
ESSA Pharma (EPIX) Canada $0.071B 0.00
Vivani Medical (VANI) United States $0.070B 0.00
Scienture Holdings (SCNX) United States $0.070B 0.00
OptiNose (OPTN) United States $0.064B 0.00
Mural Oncology (MURA) Ireland $0.053B 0.00
AlloVir (ALVR) United States $0.052B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.050B 0.00
Prelude Therapeutics (PRLD) United States $0.049B 0.00
Iterum Therapeutics (ITRM) Ireland $0.048B 0.00
Nutriband (NTRB) United States $0.047B 0.00
Rafael Holdings (RFL) United States $0.044B 0.00
Gain Therapeutics (GANX) United States $0.042B 0.00
CASI Pharmaceuticals (CASI) China $0.042B 0.00
SCYNEXIS (SCYX) United States $0.038B 0.00
BioVie (BIVI) United States $0.037B 0.00
FibroGen (FGEN) United States $0.036B 0.00
VYNE Therapeutics (VYNE) United States $0.035B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.033B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.033B 0.00
Surrozen (SRZN) United States $0.032B 0.00
Incannex Healthcare (IXHL) Australia $0.031B 0.00
Tempest Therapeutics (TPST) United States $0.031B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.031B 0.00
DURECT (DRRX) United States $0.027B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
Enlivex Therapeutics (ENLV) Israel $0.025B 0.00
Lipocine (LPCN) United States $0.025B 0.00
Vivos Therapeutics (VVOS) United States $0.023B 0.00
Mannatech (MTEX) United States $0.022B 0.00
Citius Pharmaceuticals (CTXR) United States $0.019B 0.00
Carisma Therapeutics (CARM) United States $0.018B 0.00
NRx Pharmaceuticals (NRXP) United States $0.018B 0.00
PolyPid (PYPD) Israel $0.017B 0.00
MEI Pharma (MEIP) United States $0.016B 0.00
BioLineRx (BLRX) Israel $0.016B 0.00
Traws Pharma (TRAW) United States $0.016B 0.00
ProPhase Labs (PRPH) United States $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.015B 0.00
Cosmos Health (COSM) United States $0.014B 0.00
GlycoMimetics (GLYC) United States $0.013B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.013B 0.00
TherapeuticsMD (TXMD) United States $0.013B 0.00
Nuvilex (PMCB) United States $0.011B 0.00
Lyra Therapeutics (LYRA) United States $0.011B 0.00
Relmada Therapeutics (RLMD) United States $0.011B 0.00
Talphera (TLPH) United States $0.011B 0.00
Jaguar Animal Health (JAGX) United States $0.010B 0.00
Klotho Neurosciences (KLTO) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Indaptus Therapeutics (INDP) United States $0.009B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.009B 0.00
Viracta Therapeutics (VIRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
Dominari Holdings (DOMH) United States $0.008B 0.00
Redhill Biopharma (RDHL) Israel $0.008B 0.00
CERo Therapeutics Holdings (CERO) United States $0.008B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.008B 0.00
Conduit Pharmaceuticals (CDT) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.007B 0.00
Bio-Path Holdings (BPTH) United States $0.006B 0.00
Ainos (AIMD) United States $0.006B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Plus Therapeutics (PSTV) United States $0.006B 0.00
Biomerica (BMRA) United States $0.004B 0.00
TNF Pharmaceuticals (TNFA) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Aptorum Group (APM) United Kingdom $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.004B 0.10
SHINECO (SISI) China $0.004B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
TransCode Therapeutics (RNAZ) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Molecular Templates (MTEM) United States $0.002B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Phio Pharmaceuticals (PHIO) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.001B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.001B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
Jupiter Neurosciences (JUNS) United States $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 4.69
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 41.84